Oral Icotrokinra Improves Ulcerative Colitis Response in Phase 2 Trial
Phase 2b trial found oral icotrokinra outperformed placebo for week 12 clinical response in moderately to severely active ulcerative colitis.
Digestive disease, hepatology, endoscopy and inflammatory bowel disease.
Digestive disease, hepatology, endoscopy and inflammatory bowel disease.